1. Clinical Information System Jamie RenfroBecky SigrestDanielle Russell 2. Overview of a CISClinical Information Systems (CIS) consists of information technology that is…

1. Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA ASH 2012: New JAK Inhibitors…

1. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerEric…

Slide 1Epidemiology and Outcomes of IA in the 21st Century: Strengths and Weaknesses of Surveillance Databases Dionissios Neofytos, MD, MPH Transplant & Oncology Infectious…

Slide 1Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study Dirk Blom,…

Slide 1Apixaban Dosing To Optimize Protection From Thrombosis (ADOPT) Trial Sponsored by Bristol-Myers Squibb and Pfizer Samuel Z. Goldhaber, MD Brigham and Womens Hospital…

Slide 1Research and Development in Pulmonary Fibrosis: The Future is Bright Glenn D. Rosen, M D Associate Professor of Medicine Interim Co-Chief and Program Director Pulmonary…

Folie 1 Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX) as first-line treatment for metastatic colorectal cancer: safety and efficacy…

1. Improving Stroke Care in North Carolina: The WFBH Telestroke Program Charles H. Tegeler, MD McKinney-Avant Professor of Neurology Director, Telestroke Services Director,…

1. EXPLORE-Xa A Phase 2, Randomized, Parallel Group, Dose‑Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses…